INmune Bio has become a founding member of the American Biotech Innovation Alliance (ABIA), a coalition of 26 biotech companies aiming to develop a national strategy to maintain US leadership in biotechnology. The alliance will focus on key industry challenges like manufacturing capacity, research investment, regulatory flexibility, and workforce development. This collaboration seeks to strengthen the US biotech ecosystem amid global competition and supply chain shifts. INmune Bio and other members will contribute to ABIA's Vision 2030 strategy to ensure continued innovation and patient-centric therapies.
FDA Commissioner Marty Makary has resigned, ending a turbulent tenure marked by internal dysfunction and criticism from drugmakers, physicians, and patient groups. His leadership faced backlash over regulatory decisions, including rejections of rare ...
Moderna is leveraging artificial intelligence extensively to accelerate drug development, including a hantavirus vaccine. Since partnering with OpenAI in 2023, Moderna has deployed over 750 AI models to streamline scientific and operational workflows...
Moderna's stock has rallied following news of its early-stage hantavirus vaccine research. The biotech company is conducting pre-clinical work with the U.S. Army and has partnered since 2024 with the Vaccine Innovation Center at Korea University Coll...
Moderna's stock has gained more than 16% in five days following reports of its early-stage hantavirus vaccine development. The company is expanding its infectious disease research pipeline, although hantavirus's commercial potential is limited due to...
Moderna's stock rose about 6% following reports of a Hantavirus outbreak and the company's early-stage mRNA vaccine research targeting the virus. This surge extends Moderna's strong 2026 performance, with shares up 95% year-to-date, outperforming Pfi...
